Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study

Gabrielle Campbell; Richard Mattick; Raimondo Bruno; Briony Larance; Suzanne Nielsen; Milton Cohen; Nicholas Lintzeris; Fiona Shand; Wayne D Hall; Bianca Hoban; Chyanne Kehler; Michael Farrell; Louisa Degenhardt

doi:10.1186/2050-6511-15-17

Back

Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study

Journal article

Open access

Peer reviewed

Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study

Gabrielle Campbell, Richard Mattick, Raimondo Bruno, Briony Larance, Suzanne Nielsen, Milton Cohen, Nicholas Lintzeris, Fiona Shand, Wayne D Hall, Bianca Hoban, …

BMC pharmacology & toxicology, Vol.15, pp.1-9

2014

DOI: https://doi.org/10.1186/2050-6511-15-17

PMCID: PMC4000138

PMID: 24646721

Files and links (2)

pdf

Cohort protocol paper - the Pain and Opioids In Treatment POINT study355.74 kBDownload View

Published VersionCCBY_V2.0, Open Access

url

https://doi.org/10.1186/2050-6511-15-17View

Published Version

Abstract

Opioid-Related Disorders - epidemiology

Practice Patterns, Physicians' - statistics & numerical data

Analgesics, Opioid - adverse effects

Chronic Pain - drug therapy

Drug Overdose - epidemiology

Humans

Adolescent

Analgesics, Opioid - therapeutic use

Treatment Outcome

Australia - epidemiology

Drug Utilization - statistics & numerical data

Cohort Studies

Internationally, there is concern about the increased prescribing of pharmaceutical opioids for chronic non-cancer pain (CNCP). In part, this is related to limited knowledge about the long-term benefits and outcomes of opioid use for CNCP. There has also been increased injection of some pharmaceutical opioids by people who inject drugs, and for some patients, the development of problematic and/or dependent use. To date, much of the research on the use of pharmaceutical opioids among people with CNCP, have been clinical trials that have excluded patients with complex needs, and have been of limited duration (i.e. fewer than 12 weeks). The Pain and Opioids In Treatment (POINT) study is unique study that aims to: 1) examine patterns of opioid use in a cohort of patients prescribed opioids for CNCP; 2) examine demographic and clinical predictors of adverse events, including opioid abuse or dependence, medication diversion, other drug use, and overdose; and 3) identify factors predicting poor pain relief and other outcomes. The POINT cohort comprises around 1,500 people across Australia prescribed pharmaceutical opioids for CNCP. Participants will be followed-up at four time points over a two year period. POINT will collect information on demographics, physical and medication use history, pain, mental health, drug and alcohol use, non-adherence, medication diversion, sleep, and quality of life. Data linkage will provide information on medications and services from Medicare (Australia's national health care scheme). Data on those who receive opioid substitution therapy, and on mortality, will be linked. This study will rigorously examine prescription opioid use among CNCP patients, and examine its relationship to important health outcomes. The extent to which opioids for chronic pain is associated with pain reduction, quality of life, mental and physical health, aberrant medication behavior and substance use disorders will be extensively examined. Improved understanding of the longer-term outcomes of chronic opioid therapy will direct community-based interventions and health policy in Australia and internationally. The results of this study will assist clinicians to better identify those patients who are at risk of adverse outcomes and who therefore require alternative treatment strategies.

Details

Title: Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study
Authors: Gabrielle Campbell (Author) - UNSW Australia
Richard Mattick (Author) - UNSW Australia
Raimondo Bruno (Author) - UNSW Australia
Briony Larance (Author) - UNSW Australia
Suzanne Nielsen (Author) - UNSW Australia
Milton Cohen (Author) - St Vincent's Hospital Sydney
Nicholas Lintzeris (Author) - The University of Sydney
Fiona Shand (Author) - UNSW Australia
Wayne D Hall (Author) - The University of Queensland
Bianca Hoban (Author) - UNSW Australia
Chyanne Kehler (Author) - UNSW Australia
Michael Farrell (Author) - UNSW Australia
Louisa Degenhardt (Author) - UNSW Australia
Publication details: BMC pharmacology & toxicology, Vol.15, pp.1-9
Location: Australia
Publisher: BioMed Central Ltd.
Date published: 2014
DOI: 10.1186/2050-6511-15-17
ISSN: 2050-6511
PMID: 24646721; PMC4000138
Copyright note: © 2014 Campbell et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Organisation Unit: University of the Sunshine Coast, Queensland; School of Health and Sport Sciences - Legacy; School of Health and Behavioural Sciences - Legacy
Language: English
Record Identifier: 99473408402621
Output Type: Journal article

Metrics

1 File views/ downloads

26 Record Views

39 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Web Of Science research areas: Pharmacology & Pharmacy; Toxicology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites